

**Supplementary Table 1.** The Expression of Apolipoproteins in SCLC Tissues Under Different Conditions

Characteristics		ApoA-1		ApoC-III		ApoE	
Gender	Men (60)	26.7% (16/60)	76.7% (44/60)	41.7% (25/60)	58.3% (35/60)	23.1% (14/60)	76.7% (46/60)
	Women (29)	27.6% (8/29)	72.4% (21/29)	41.4% (12/29)	58.6% (17/29)	20.7% (6/29)	79.3% (23/29)
Stage	I (12)	25% (3/12)	75% (9/12)	50% (6/12)	50% (6/12)	25% (3/12)	75% (8/12)
	II (19)	31.6% (6/19)	68.4% (13/19)	31.6% (6/19)	68.4% (13/19)	36.8% (7/19)	63.2% (12/19)
	III (52)	31.0% (9/29)	69.0% (20/29)	48.3% (14/29)	51.7% (15/29)	17.2% (5/29)	82.8% (24/29)
	IV (4)	25% (1/4)	75% (3/4)	0% (0/4)	100% (4/4)	25% (1/4)	75% (3/4)
Two cases were excluded because re-inspection was not performed							
Metastasis	N0 (24)	25% (6/24)	75% (18/24)	45.8% (11/24)	54.2% (13/24)	25% (6/24)	75% (18/24)
	N1 (22)	36.4% (8/22)	63.6% (14/22)	27.3% (6/22)	81.8% (16/22)	31.8% (7/22)	68.2% (14/22)
	N2 (35)	22.9% (8/35)	77.1% (27/35)	48.6% (17/35)	51.4% (18/35)	22.9% (8/35)	77.1% (27/35)
	N3 (2)	0% (0/2)	100% (2/2)	50% (1/1)	50% (1/1)	0% (0/2)	100% (2/2)
NX (7 cases; excluded because patients were treated in other hospitals)							
Tumor size	T1a (6)	33.3% (2/6)	66.7% (4/6)	50% (3/6)	50% (3/6)	16.7% (1/6)	83.3% (5/6)
	T1b (10)	30% (3/10)	70% (7/10)	30% (3/10)	70% (7/10)	20% (2/6)	80% (8/10)
	T2a (16)	25% (4/16)	75% (12/16)	31.3% (5/16)	68.7% (11/16)	37.5% (6/16)	62.5% (10/16)
	T2b (10)	10% (1/10)	90% (9/10)	40% (4/10)	60% (6/10)	20% (2/10)	80% (8/10)
	T3 (12)	50% (6/12)	50% (6/12)	66.6% (8/12)	33.4% (4/12)	25% (3/12)	75% (9/12)
	T4 (28)	28.6% (8/28)	71.4% (20/28)	42.9% (12/28)	57.1% (16/28)	21.4% (6/28)	78.6% (22/28)
TX 7 (7 cases; excluded because patients were treated in other hospitals)							

SCLC, small cell lung cancer.